Bactericidal Activities of Peptide Antibiotics Against Multidrug-resistant Enterococcus Faecium

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1994 Feb 1

PMID 8192473

Citations 16

Authors

N Mobarakai

J M Quale

D Landman

Affiliations

Soon will be listed here.

Abstract

Multidrug-resistant Enterococcus faecium has emerged as a serious pathogen for which no effective therapy has been established. In this report, we describe the activities of two peptide antibiotics, ramoplanin and daptomycin, against 15 isolates of E. faecium resistant to vancomycin, ampicillin, and aminoglycosides using time-kill experiments. Both antibiotics were rapidly bactericidal when tested in broth; however, the addition of 50% serum resulted in significant regrowth. The combination of ampicillin with either ramoplanin or daptomycin largely prevented this regrowth. These peptide antibiotics showed good activity against these pathogens. While the development of daptomycin has been halted, ramoplanin may hold promise for the therapy of multidrug-resistant E. faecium, especially when combined with ampicillin.

Citing Articles

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Hindler J, Wong-Beringer A, Charlton C, Miller S, Kelesidis T, Carvalho M Antimicrob Agents Chemother. 2015; 59(7):4279-88.

PMID: 25963982 PMC: 4468720. DOI: 10.1128/AAC.05077-14.

Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in Staphylococcus aureus.

Cheng M, Huang J, Ramu S, Butler M, Cooper M Antimicrob Agents Chemother. 2014; 58(11):6819-27.

PMID: 25182650 PMC: 4249368. DOI: 10.1128/AAC.00061-14.

Pharmacological properties of NAI-603, a well-tolerated semisynthetic derivative of ramoplanin.

Jabes D, Brunati C, Candiani G, Riva S, Romano G, Maffioli S Antimicrob Agents Chemother. 2014; 58(4):1922-9.

PMID: 24419352 PMC: 4023767. DOI: 10.1128/AAC.01620-13.

Identification of a novel antimicrobial peptide from human hepatitis B virus core protein arginine-rich domain (ARD).

Chen H, Su P, Chang Y, Wu S, Liao Y, Yu H PLoS Pathog. 2013; 9(6):e1003425.

PMID: 23785287 PMC: 3681751. DOI: 10.1371/journal.ppat.1003425.

Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

Sakoulas G, Bayer A, Pogliano J, Tsuji B, Yang S, Mishra N Antimicrob Agents Chemother. 2011; 56(2):838-44.

PMID: 22123698 PMC: 3264218. DOI: 10.1128/AAC.05551-11.

References

Garrison M, Rotschafer J, Crossley K . Suboptimal effect of daptomycin in the treatment of bacteremias. South Med J. 1989; 82(11):1414-5. DOI: 10.1097/00007611-198911000-00018. View

Facklam R, Collins M . Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol. 1989; 27(4):731-4. PMC: 267406. DOI: 10.1128/jcm.27.4.731-734.1989. View

Garrison M, Larson T, Toscano J, Rotschafer J . Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1990; 34(10):1925-31. PMC: 171966. DOI: 10.1128/AAC.34.10.1925. View

Bingen E, Lambert-Zechovsky N, Leclercq R, Doit C, Mariani-Kurkdjian P . Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 1990; 26(5):619-26. DOI: 10.1093/jac/26.5.619. View

Bartoloni A, Colao M, Orsi A, Dei R, Giganti E, Parenti F . In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother. 1990; 26(5):627-33. DOI: 10.1093/jac/26.5.627. View

Leclercq R, Bingen E, Su Q, Courvalin P, Duval J . Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother. 1991; 35(1):92-8. PMC: 244947. DOI: 10.1128/AAC.35.1.92. View

Grayson M, Eliopoulos G, Wennersten C, Ruoff K, De Girolami P, Ferraro M . Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother. 1991; 35(11):2180-4. PMC: 245356. DOI: 10.1128/AAC.35.11.2180. View

Handwerger S, Perlman D, Altarac D, McAULIFFE V . Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis. 1992; 14(3):655-61. DOI: 10.1093/clinids/14.3.655. View

Lee B, Sachdeva M, Chambers H . Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991; 35(12):2505-8. PMC: 245421. DOI: 10.1128/AAC.35.12.2505. View

10.

Allen N, Alborn Jr W, Hobbs Jr J . Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 1991; 35(12):2639-42. PMC: 245446. DOI: 10.1128/AAC.35.12.2639. View

11.

Livornese Jr L, Dias S, Samel C, Romanowski B, Taylor S, May P . Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med. 1992; 117(2):112-6. DOI: 10.7326/0003-4819-117-2-112. View

12.

Rybak M, Bailey E, Lamp K, Kaatz G . Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother. 1992; 36(5):1109-14. PMC: 188844. DOI: 10.1128/AAC.36.5.1109. View

13.

Shonekan D, Mildvan D, Handwerger S . Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother. 1992; 36(7):1570-2. PMC: 191623. DOI: 10.1128/AAC.36.7.1570. View

14.

Spera Jr R, Farber B . Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA. 1992; 268(18):2563-4. View

15.

Johnson C, Taylor S, Pitsakis P, May P, Levison M . Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother. 1992; 36(10):2342-5. PMC: 245501. DOI: 10.1128/AAC.36.10.2342. View

16.

Collins L, Eliopoulos G, Wennersten C, Ferraro M, Moellering Jr R . In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993; 37(6):1364-6. PMC: 187967. DOI: 10.1128/AAC.37.6.1364. View

17.

Stratton C, Liu C, Ratner H, Weeks L . Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother. 1987; 31(7):1014-6. PMC: 174863. DOI: 10.1128/AAC.31.7.1014. View

18.

Uttley A, Collins C, Naidoo J, George R . Vancomycin-resistant enterococci. Lancet. 1988; 1(8575-6):57-8. DOI: 10.1016/s0140-6736(88)91037-9. View

19.

Debbia E, Pesce A, Schito G . In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob Agents Chemother. 1988; 32(2):279-81. PMC: 172154. DOI: 10.1128/AAC.32.2.279. View

20.

Somner E, Reynolds P . Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother. 1990; 34(3):413-9. PMC: 171607. DOI: 10.1128/AAC.34.3.413. View